



Nexstim

Targeting a paradigm shift in stroke rehabilitation

Martin Jamieson | CEO & Chairman of the Board | Nexstim

BioTrinity, London, 26 April 2016

 @NexstimOyj

Important information

This document and the information contained herein are being presented by Nexstim Oyj (“**Nexstim**” or the “**Company**”). In connection with any presentation or review of this document, you agree to be bound by the following limitations and notifications.

This document and the information contained herein are being provided to you solely for your information. The distribution of this document in some jurisdictions may be restricted by law and persons into whose possession this document comes are required to inform themselves about and observe any such restrictions. Accordingly, this document may not be distributed in any jurisdiction except under circumstances that will result in compliance with applicable laws and regulations.

This document is not a prospectus, and the information contained herein does not and is not intended to constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any securities in connection with this document in any jurisdiction. This document and the information contained herein are not an offer of securities in the United States and are not for distribution in the United States.


Recipients should not treat the contents of the document as advice relating to legal, taxation or other matters. This presentation does not purport to be all-inclusive or to contain any or all the information that prospective investors may desire in analysing and deciding whether or not to hold or transact in the Company’s shares. Neither the Company nor any of its affiliates or representatives makes any representation or warranty, express or implied, as to the accuracy or completeness of this document or any of the information contained herein, or any other written or oral communication transmitted or made available to the recipient or its affiliates or representatives. The Company and its affiliates or representatives expressly disclaim to the fullest extent permitted by law any and all liability based, in whole or in part, on this document or any information contained herein or any other written or oral communication transmitted or made available to the recipient or its affiliates or representatives, including, without limitation, with respect to errors therein or omissions therefrom.

Recipients should not assume that the information in this document is accurate as of any date other than the date of this presentation. Nothing contained herein is, or should be relied upon as, a promise or representation as to future performance. The Company does not undertake any obligation to update or revise this this document.

Certain of the information contained herein concerning industry and market data, economic trends, market position and competitiveness is based upon or derived from information provided by third-party consultants and other industry sources. Neither the Company nor any of its affiliates or representatives can guarantee the accuracy of such information or has independently verified the assumptions upon which projections of future trends and performance in such information are based.


statements as a result of various factors. To the extent that this document contains opinions, estimates, forecasts or other forward looking statements, no guarantees or undertakings that these are correct or complete are given by the Company or any of its respective members, advisors, officers or employees or any other person. Forecasts and assumptions which are subject to economic and competitive uncertainty are outside such person’s control and no guarantee can be given that projected results will be achieved or that outcomes will correspond with forecasts. Information in this document may be changed, added to or corrected without advance notification.

Introducing Nexstim – The Navigated Brain Stimulation Company



NBS (Navigated Brain Stimulation) Pre-Surgical Mapping makes the difference to clinical outcome

Progression-free Survival (Months)



¹ Dietmar Frey, Peter Vajkoczy, and Thomas Picht **Navigated transcranial magnetic stimulation improves the treatment outcome in patients with brain tumors in motor eloquent locations** Neuro Oncology 2014 : nou110v1-nou110

NBS provides a strong platform for therapeutic applications

Accuracy

- Proven proprietary accuracy validated with neurosurgery provides accuracy for multiple therapeutic stimulation indications

Repeatability


- Accuracy provides inter-session repeatability for therapeutic protocols to maximize the effect

Precise Dose Control

- Accuracy and repeatability enable precise dose control and delivery to the intended target


Nexstim Platform provides new approach to non-invasive neuromodulation

NBT has potential for multiple indications due to precise navigation




NBT[®] (Navigated Brain Therapy) for stroke rehabilitation – how it works

Validated e-Field Navigation gives Competitive Edge



Using a patient's own MRI scan as a guide, Nexstim provides precisely targeted, personalized, magnetic stimulation to temporarily inhibit the healthy side of the brain, normalising the balance between the hemispheres.



Because the injured side is no longer dominated by the healthy side of the brain, it is more responsive to the physiotherapy. This results in limb movement being potentially restored more quickly to better functionality.

Market opportunity in stroke rehabilitation

Nexstim's Navigated Brain Therapy® solution for stroke rehabilitation



Targeting a blockbuster market...

(market for post-acute stroke treatment)

- 2.1 million strokes each year in US and Europe
- \$8.5bn annual spend on stroke rehab in the US with marginal benefits





Huge unmet need and commercial opportunity



...for a potential game-changer technology

- Validated technology
- Targeting 712,000 patients with upper limb paralysis
- Focus on period 3 months post stroke
- \$1.8 billion market potential for Nexstim

Clinical evidence from NICHE, Phase III multi-center trial



- The clinical Phase III multi-center stroke trial was stopped after 138 patients at end of March 2016
- Significant and clinically meaningful responses from both active and sham patient groups
- Dr. Richard Harvey² (RIC) “The overall level of functional improvement in NICHE is high for this post-acute stroke patient population. This degree of therapeutic response is a very positive step forward for arm and hand recovery in patients with stroke. Further exploration of this technology to enhance the current rehabilitation outcomes to this extent is a next step to pursue.”
- No safety concerns were observed with any of the 199 patients enrolled in the trial
- Nexstim will submit the FDA 510(k) De Novo based on the clinical data in the second quarter 2016

² Dr. Richard Harvey, Medical Director, Center for Stroke Rehabilitation, Rehabilitation Institute of Chicago (RIC)

Platform protected with 26 patent families

- 80 granted patents, 76 pending
- **Right to software:** Nexstim owns rights to its NBT[®] and NBS Systems' software developed in-house.
- **Core algorithms kept as trade secrets**



Summary and future outlook

- World-leading medical technology and software with game-changing potential
- Growing sales of NBS Systems expected for pre-surgical mapping. Based on its business forecast the Company estimates its net sales to grow during financial year 2016 and a loss is expected for the financial year.
- Nexstim will submit the FDA 510(k) De Novo in the second quarter 2016
- Focus on developing US stroke therapy commercialization with strengthened Board and management team
- Nexstim is investigating other potential indications for the platform





Nexstim

Thank you